Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening

Gynecologic Oncology

Volumn 119, Issue 2, 2010, Pages 237-242

  Vijayaraghavan, Arthi ^a   Efrusy, Molly B ^a   Goodman, Karyn A ^b   Santas, Christopher C ^a   Huh, Warner K ^c  

^a McKesson   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervical cancer; Cost effectiveness; Genotyping; Human papillomavirus

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; EMERGENCY HEALTH SERVICE; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIFESPAN; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED STATES; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; HUMAN; INCIDENCE; MASS SCREENING; MONTE CARLO METHOD; PAPILLOMAVIRUS INFECTIONS; PRESCHOOL CHILD; PROBABILITY; PROCEDURES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MONTE CARLO METHOD; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TRIAGE; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77957749080     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.07.004     Document Type: Article

References (36)

1. N. Munoz, F.X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, and K.V. Shah Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527 (Pubitemid 36159887)
2. C.M. Wheeler, W.C. Hunt, N.E. Joste, C.R. Key, W.G. Quint, and P.E. Castle Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States J Natl Cancer Inst 101 2009 475 487
3. Anon HPV genotyping clinical update American Society for Colposcopy and Cervical Pathology (ASCCP) 2009
4. M.H. Mayrand, E. Duarte-Franco, I. Rodrigues, S.D. Walter, J. Hanley, and A. Ferenczy Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer N Engl J Med 357 2007 1579 1588
5. P. Naucler, W. Ryd, S. Tornberg, A. Strand, G. Wadell, and K. Elfgren Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening J Natl Cancer Inst 101 2009 88 99
6. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, and A. Del Mistro Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test J Natl Cancer Inst 100 2008 492 501
7. J. Cuzick, M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, and M.H. Mayrand Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 Suppl 10 2008 K29 K41
8. P.E. Gravitt, F. Coutlee, T. Iftner, J.W. Sellors, W.G. Quint, and C.M. Wheeler New technologies in cervical cancer screening Vaccine 26 Suppl 10 2008 K42 K52
9. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York and Oxford 425
10. M.F. Drummond, G.L. Stoddart, and G.W. Torrance Methods for the economic evaluation of health care programmes 1987 Oxford University Press Oxford
11. A. Vijayaraghavan, M. Efrusy, G. Lindeque, G. Dreyer, and C. Santas Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa Gynecol Oncol 112 2009 377 383
12. R. Herrero, P.E. Castle, M. Schiffman, M.C. Bratti, A. Hildesheim, and J. Morales Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica J Infect Dis 191 2005 1796 1807
13. M.J. Khan, P.E. Castle, A.T. Lorincz, S. Wacholder, M. Sherman, and D.R. Scott The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 97 2005 1072 1079
14. M. Saraiya, F. Ahmed, S. Krishnan, T.B. Richards, E.R. Unger, and H.W. Lawson Cervical cancer incidence in a prevaccine era in the United States, 1998-2002 Obstet Gynecol 109 2007 360 370
15. G.M. Clifford, J.S. Smith, M. Plummer, N. Munoz, and S. Franceschi Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis Br J Cancer 88 2003 63 73
16. H. Trottier, S. Mahmud, J.C. Prado, J.S. Sobrinho, M.C. Costa, and T.E. Rohan Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination J Infect Dis 197 2008 1436 1447
17. N.F. Schlecht, R.W. Platt, E. Duarte-Franco, M.C. Costa, J.P. Sobrinho, and J.C. Prado Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia J Natl Cancer Inst 95 2003 1336 1343 (Pubitemid 37160867)
18. S. Ratnam, E.L. Franco, and A. Ferenczy Human papillomavirus testing for primary screening of cervical cancer precursors Cancer Epidemiol Biomarkers Prev 9 2000 945 951
19. J. Cuzick, C. Clavel, K.U. Petry, C.J. Meijer, H. Hoyer, and S. Ratnam Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 2006 1095 1101
20. G. Bigras, and F. de Marval The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women Br J Cancer 93 2005 575 581
21. G.D. Sanders, and A.V. Taira Cost effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 9 2003 37 48
22. M.F. Janicek, and H.E. Averette Cervical cancer: prevention, diagnosis, and therapeutics CA Cancer J Clin 51 2001 92 114
23. S. Pecorelli, H.Y. Ngan, N.F. Hacker, L. Denny, H.W. Jones III, and J. Kavanagh Staging classifications and clinical practice guidelines for gynaecological cancers Third ed. 2000 Elsevier 88
24. C.A. Perez, P.W. Grigsby, K.S.C. Chao, D.G. Mutch, and M.A. Lockett Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix Int J Radiat Oncol Biol Phys 41 1998 307 317
25. T.C. Wright Jr., L.S. Massad, C.J. Dunton, M. Spitzer, E.J. Wilkinson, and D. Solomon 2006 consensus guidelines for the management of women with abnormal cervical screening tests J Low Genit Tract Dis 11 2007 201 222 (Pubitemid 47530909)
26. T.C. Wright Jr., L.S. Massad, C.J. Dunton, M. Spitzer, E.J. Wilkinson, and D. Solomon 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ J Low Genit Tract Dis 11 2007 223 239 (Pubitemid 47530910)
27. Macroeconomics and health: investing in health for economic development: report of the Commission on Macroeconomics and Health 2001 World Health Organization Geneva
28. R. Sankaranarayanan, B.M. Nene, S.S. Shastri, K. Jayant, R. Muwonge, and A.M. Budukh HPV screening for cervical cancer in rural India N Engl J Med 360 2009 1385 1394
29. J.J. Kim, T.C. Wright, and S.J. Goldie Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 287 2002 2382 2390
30. S.J. Goldie, J.J. Kim, and T.C. Wright Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more Obstet Gynecol 103 2004 619 631
31. J.D. Goldhaber-Fiebert, N.K. Stout, J.A. Salomon, K.M. Kuntz, and S.J. Goldie Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination J Natl Cancer Inst 100 2008 308 320
32. J.J. Kim, M. Brisson, W.J. Edmunds, and S.J. Goldie Modeling cervical cancer prevention in developed countries Vaccine 26 Suppl 10 2008 K76 K86
33. P.E. Castle The potential utility of HPV genotyping in screening and clinical management J Natl Compr Canc Netw 6 2008 83 95
34. M. Schiffman Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing Cancer 111 2007 145 153
35. E.L. Franco, and J. Cuzick Cervical cancer screening following prophylactic human papillomavirus vaccination Vaccine 26 Suppl 1 2008 A16 A23
36. W. Huh, M.H. Einstein, T.J. Herzog, and E.L. Franco What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol Oncol 117 3 Jun 2010 481 485 Epub 2010 Apr 24